CYNAERA IACC Twin™ - How It Works
- Feb 15
- 17 min read
Updated: May 8
Author: Cynthia Adinig, CYNAERA Institute
This document follows the Aligned Intelligence Method™ (AIM), a CYNAERA framework that presents complex health information in a format that is clear for human readers and consistent for AI-assisted interpretation. It integrates longitudinal patterns, environmental context, and clinical research to support responsible interpretation of infection-associated chronic conditions.
Introduction
Most medical care is built for short illnesses. A problem appears, treatment begins, and recovery is expected to follow a steady path. Infection-associated chronic conditions do not behave this way. Symptoms can change day to day, worsen after delays, and affect multiple body systems even when routine tests look normal. This mismatch often leads to misunderstanding or dismissal of patient experiences (National Academies of Sciences, Engineering, and Medicine, 2015; Greenhalgh et al., 2020; Crook et al., 2021).
Post-exertional worsening is a key feature in ME/CFS and Long COVID. Symptoms may intensify 12 to 72 hours after activity, a delay that a single clinic visit cannot capture (Jason et al., 2018; Davis et al., 2023). When care relies on snapshots, this lag can be mistaken for anxiety, deconditioning, or lack of effort.
Autonomic dysfunction adds another layer. Heart rate, blood pressure, and blood flow to the brain can shift with posture, temperature, hydration, and time of day (Raj et al., 2013; Miglis et al., 2020). Without tracking over time, these changes may be misread as psychological rather than physiologic.
Environmental factors also play a role. Air pollution, heat, mold, and chemical exposures can worsen symptoms, yet these triggers are rarely recorded in medical visits (Theoharides et al., 2020; Crook et al., 2021). When context is ignored, real patterns are lost.
Looking at Patterns Over Time
To understand these conditions, we must look at patterns across time instead of single events. Research shows that symptoms, energy, sleep, and tolerance can shift based on exertion, immune activity, and environmental stress (National Academies of Sciences, Engineering, and Medicine, 2015; Davis et al., 2021; Iwasaki et al., 2023).
When symptoms change, they are often treated as noise. In infection-associated chronic illness, change is part of the disease. Crashes after activity, flares during weather shifts, and brief improvements followed by relapse are not random. They reflect unstable regulation (Crook et al., 2021; Davis et al., 2023).
Separating observation from interpretation is essential. Recording that fatigue worsened two days after exertion preserves useful information. Concluding that the patient “overdid it” introduces bias. Keeping these separate supports safer research and clearer communication (Greenhalgh et al., 2020).
Environmental and Context Factors That Affect Stability
People with infection-associated chronic illness often react strongly to their surroundings. Changes in air quality, temperature, humidity, chemicals, noise, and travel can affect symptoms and recovery. These factors are rarely documented in medical records but can strongly influence daily stability (Theoharides et al., 2020; Miglis et al., 2020).
Environmental stress can increase inflammation, disrupt sleep, and worsen autonomic symptoms. Wildfire smoke and air pollution can intensify fatigue and cognitive problems. Heat and rapid pressure changes can worsen dizziness and heart rate instability. Mold and chemical exposures may trigger mast cell activation and neuroimmune responses (Crook et al., 2021; Davis et al., 2023). Context matters because multiple changes often happen at once. A medication change during a smoke event or heat wave may appear to fail when the true driver is environmental stress. Recognizing context helps avoid false conclusions and supports stability-first decisions.
Dose Sensitivity in High-Risk Patients
Many people with infection-associated chronic illness are highly sensitive to medications and supplements. Standard starting doses may cause strong reactions or delayed worsening. This pattern is observed in ME/CFS, dysautonomia, mast cell disorders, and other conditions involving immune and autonomic instability (National Academies of Sciences, Engineering, and Medicine, 2015; Raj et al., 2022; Theoharides et al., 2020).
Delayed reactions are especially important. Symptoms may worsen hours or days after starting or increasing a dose. This reflects nonlinear responses in systems already under strain (Naviaux, 2016; Klimas et al., 2012), as mentioned in the Primary Chronic Trigger (PCT) Model.
Common patterns of dose sensitivity include:
• worsening symptoms a day or more after starting a medication
• short improvement followed by relapse
• new symptoms appearing days later
• increased sensitivity during environmental stress
• sleep disruption after dose changes
These responses do not always mean a treatment is wrong. They may indicate that timing, dose, or context needs adjustment. Slower starts and longer observation periods help distinguish true benefit from delayed adverse effects (Greenhalgh et al., 2020; Crook et al., 2021).
Hormone-Related Symptom Changes
Hormone shifts can affect symptoms, sleep, energy, and how the body responds to treatments. Many people with infection-related chronic illness notice changes that seem unpredictable until hormone timing is considered.
These patterns are often overlooked in care, even though research shows hormones influence immune activity, autonomic function, and mast cell behavior (Theoharides et al., 2020; Angum et al., 2020; Klein & Flanagan, 2016).
People may notice patterns such as symptoms worsening at the same time each month, sleep disruption before or during a cycle, or changes in medication tolerance across the month. New instability during perimenopause is also common, reflecting shifts in estrogen and progesterone that affect inflammation and vascular regulation (Angum et al., 2020).
This context matters because a stable treatment may appear to “stop working” when hormone changes are the real driver. Without this awareness, normal physiologic cycles may be mistaken for treatment failure.
When hormone-related patterns are present, the model prioritizes stability. Observation periods may be extended, dose changes delayed, and environmental stress considered alongside cycle timing. These safeguards reduce false conclusions and improve pattern recognition.
Primary Chronic Trigger (PCT)
Many infection-associated chronic conditions begin after a clear turning point. CYNAERA calls this shift a Primary Chronic Trigger, or PCT. A PCT may include infection, immune disruption, environmental exposure, trauma, or another major physiologic stressor.
After this shift, the body may stop returning to its prior baseline. Ordinary inputs such as walking, sleep loss, or environmental exposures can trigger delayed or outsized reactions. This lagged and nonlinear response pattern is well described in post-viral illness and ME/CFS trajectories (National Academies of Sciences, Engineering, and Medicine, 2015; Davis et al., 2023; Komaroff & Bateman, 2021).
PCT is not used to prove causation. Instead, it marks the point where the system’s response rules changed. This helps explain why tolerance collapses after minor stress and why symptoms fluctuate even when tests appear normal.
Why PCT matters in IACC Digital Twin™ modeling
Identifying a PCT helps the model avoid common reasoning errors. It prevents short-term symptom changes from being mistaken for recovery and avoids assuming the most recent exposure is the cause when delayed payback is present (Institute of Medicine, 2015; Komaroff & Bateman, 2021).
Stabilization and Remission
Recovery in infection-associated chronic illness rarely follows a straight line. Instead of a single “recovered” point, people often move through stages of stability and improved tolerance. These are pattern states, not medical endpoints.
Strict labels such as “sick” or “recovered” miss meaningful change. Pattern states help patients describe progress, help clinicians see trends, and help researchers measure improvement without confusing temporary relief for lasting recovery (Crook et al., 2021; Greenhalgh et al., 2020). Improvement is not the absence of symptoms. Improvement is increased stability and tolerance.
Common stability and improvement states
Unstable
Frequent crashes, expanding triggers, and slow recovery.
• symptoms worsen often
• recovery takes longer than usual
• new triggers appear
• daily function is unpredictable
Stabilizing
Crashes still occur, but recovery becomes more predictable.
• longer time between flares
• recovery time begins to shorten
• fewer new triggers
• small increases in activity are tolerated
Stable
Symptoms remain within a usual range.
• daily function is more predictable
• flares follow familiar patterns
• recovery is consistent
• triggers are identifiable
Functional remission
Stability holds and tolerance expands.
• increased activity without crashes
• improved sleep and recovery
• reduced sensitivity to triggers
• wider safe zone for daily life
Functional remission does not mean cure. It means stability with improved capacity.
Why this language is safer
Describing remission as a pattern state avoids false promises of cure, prevents dismissal of partial recovery, and supports realistic expectations. This approach improves communication across care teams and aligns with modern thinking on chronic illness outcomes (Greenhalgh et al., 2020; Crook et al., 2021; Komaroff & Bateman, 2021).
How GPTs use stability states
The system uses this language to describe trends without making clinical claims. It may note increased stability, reduced crash frequency, or expanding tolerance. It does not diagnose or declare remission. It describes patterns.
Stability states can often be identified using small signals such as crash frequency, recovery time, activity tolerance, sleep stability, and trigger sensitivity. Incomplete data reduces detail, not credibility.
Unified Network Collapse Theory (UNCT)
The Unified Network Collapse Theory explains why many infection-associated chronic conditions look different on the surface but share a common pattern of instability. The body functions as a network of connected systems, including immune signaling, autonomic regulation, hormones, metabolism, and vascular function.
When one system is pushed beyond its reserve, others compensate. Over time, this compensation can fail across multiple systems, creating clusters of symptoms that seem unrelated but reflect shared instability (Davis et al., 2023; Raj et al., 2022; Naviaux, 2016), as mentioned in the IACC Digital Twin framework.
People may experience combinations such as fatigue, heart rate instability, brain fog, sleep disruption, and sensitivity to foods or chemicals. Autonomic dysfunction is common in Long COVID and strongly linked to quality of life, which is why UNCT treats autonomic stability as a central network marker (Raj et al., 2022; Miglis et al., 2020).
Using Everyday Information Without Extra Burden
People living with chronic illness often do not have the energy to track every detail. Many also experience cognitive fatigue, which makes complex logging systems unrealistic. For this reason, the Digital Twin model is designed to work with information people already have rather than requiring new tools or intensive tracking (National Academies of Sciences, Engineering, and Medicine, 2015; Greenhalgh et al., 2020; Jason et al., 2018).
Useful details often exist in daily life rather than in specialized apps. A calendar entry that shows when symptoms worsened, a pharmacy refill date that marks a medication change, or a weather alert during a flare can all provide meaningful context. Phone step counters, patient portal summaries, period tracking apps, and even brief notes or text messages often contain enough signal to reveal patterns when viewed over time. This approach follows a simple principle: use what already exists.
Incomplete information does not reduce credibility. It reduces detail. Even small pieces of information can help identify trends in conditions marked by delayed response and fluctuating function (Crook et al., 2021; Davis et al., 2023). The goal is not perfect tracking. The goal is recognizing patterns without adding burden.
Prompt Templates and Minimum Inputs
People do not need perfect records to describe their experience. A few details can greatly improve clarity and help separate timing, context, and possible influences. These examples are optional and meant to reduce effort, not add work.
A statement such as “I started a new medication and feel worse” is understandable but lacks timing and context. In conditions with delayed responses, missing details can make patterns harder to interpret (Davis et al., 2023; Komaroff & Bateman, 2021).
Adding simple anchors helps clarify what changed without requiring a full log. Even short notes can help distinguish treatment effects from background fluctuations.
Example 1: Medication change
Minimal note
“I started a new medication and feel worse.”
Low-effort version
“Started metoprolol Monday.
By Wednesday: more fatigue and dizziness.
Sleep worse. No other changes.”
Why this helps
Adds timing and shows delayed effects, which are common in autonomic conditions.
Example 2: Activity increase
Minimal note
“I tried to do more and crashed.”
Low-effort version
“Walked 15 minutes Saturday instead of my usual 5.
Felt okay that day.
Monday: heavy fatigue and body pain.”
Why this helps
Shows delayed post-exertional worsening, a core feature of ME/CFS-type patterns (Jason et al., 2018).
Example 3: Environmental trigger
Minimal note
“My symptoms were bad today.”
Low-effort version
“Bad brain fog and heart racing today.
Air quality alert for smoke.
Stayed indoors but smell still present.”
Why this helps
Connects symptoms with environmental load, which often goes unrecorded in clinical care (Theoharides et al., 2020).
Example 4: Hormonal pattern
Minimal note
“My meds stopped working.”
Low-effort version
“Symptoms worse 2 days before period again.
Sleep poor.
Same meds and routine.”
Why this helps
Suggests a cyclic pattern rather than treatment failure.
Example 5: Low-energy entry
On difficult days, even fragments provide useful signal.
“New supplement 2 days ago.
Heart racing.
Slept 3 hours.”
Short entries still help identify patterns over time.
When more energy is available
If a person has more capacity, a little added context can improve interpretation:
“I started ivabradine on May 3 for heart rate control.
Before starting, I could sit up for 30 minutes.
Since starting, I feel less tachycardia but more fatigue.
This week also had a heat wave.”
These details help separate treatment effects from overlapping influences such as temperature stress (Greenhalgh et al., 2020).
Why examples matter
Real-world language improves participation. People are more likely to share information when they see that partial notes are valid and useful. This is especially important in conditions marked by cognitive fatigue and delayed symptom patterns (Institute of Medicine, 2015; Davis et al., 2021). The goal is not perfect data. The goal is a usable signal.
Evidence Use and Reference Guidance
IACC Digital Twin™ uses published research to support pattern recognition and provide context, while recognizing that evidence alone cannot capture the lived complexity of infection-associated chronic conditions. Combining research with patient-reported experience improves understanding and reduces misinterpretation, especially in illnesses marked by variability and delayed response (National Academies of Sciences, Engineering, and Medicine, 2015; Davis et al., 2023; Crook et al., 2021).
References are organized across topic areas such as post-viral symptom burden, post-exertional worsening, autonomic dysfunction, immune and mast cell responses, treatment burden, and social impact. When multiple domains apply, references may rotate to reflect the breadth of research rather than over-relying on a single study. This improves balance and prevents narrow interpretations.
Evidence in this model supports pattern recognition, explains possible mechanisms, frames uncertainty, and prevents oversimplification. It is not used to diagnose illness, prescribe treatment, replace clinicians, or claim certainty. Research provides context. Lived experience provides detail. Together, they improve understanding.
Designed for Low Energy and Accessibility
Many people with infection-related chronic illness live with fatigue, brain fog, pain, and sensory overload. Systems that require detailed tracking or long forms often exclude those most affected. Research shows that cognitive fatigue and post-exertional worsening limit sustained effort in ME/CFS and Long COVID, making low-effort tools essential for participation (Institute of Medicine, 2015; Jason et al., 2018; Davis et al., 2021). This model is designed to work even when energy is limited.
Accessibility principles
• short entries are valid
• incomplete information is acceptable
• fragments still provide useful signal
• no penalty for inconsistency
• fewer steps reduce cognitive strain
By allowing simple inputs, the model includes people who are often left out of research and care. If only high-energy users can participate, the most severe cases remain invisible. Designing for low energy improves both equity and data accuracy (Greenhalgh et al., 2020).
Safety Boundaries
The IACC Digital Twin™ is designed to support understanding, not to replace medical care. Clear boundaries protect users, clinicians, and researchers by preventing misuse and reducing the risk of false conclusions. In complex chronic illness, symptoms often change due to delayed effects, environmental conditions, or overlapping influences. Timing alone does not establish cause, and apparent patterns may reflect multiple interacting factors (National Academies of Sciences, Engineering, and Medicine, 2015; Naviaux, 2016).
Within these boundaries, the model helps identify patterns over time, highlight possible influences on symptoms, and support research, education, and advocacy. It can also improve communication between patients and clinicians by providing a shared language for describing change. At the same time, the model does not diagnose illness, prescribe treatment, recommend medication changes, or replace licensed medical care. It does not claim certainty about cause and effect. These limits are intentional. Maintaining them preserves trust, prevents overreach, and supports safer use in conditions where delayed response and variability are common (Greenhalgh et al., 2020; Crook et al., 2021). Clear scope is not a restriction. It is a safeguard that allows the model to remain useful without creating clinical risk.
Why This Matters Beyond Healthcare
Although developed for infection-related chronic illness, this approach applies to many systems where delayed effects and changing conditions shape outcomes. In these environments, single snapshots often miss important patterns, while longitudinal context improves decision-making.
Similar dynamics appear in climate and disaster response, workplace exposure tracking, public health surveillance, disability assessment, education planning, and economic recovery. In each of these areas, outcomes unfold over time, influences overlap, and information is often incomplete. Systems that preserve context and track patterns over time are better equipped to respond to real-world complexity (Crook et al., 2021; Meadows, 2008).
Healthcare serves as the testing ground because it combines biological variability with social and environmental pressures. When a model can interpret this level of complexity responsibly, it can be adapted to other domains where human systems are dynamic and conditions evolve.
A Model Built for Real Life
Infection-associated chronic illness has exposed the limits of systems designed for short-term care and simple recovery. When symptoms shift over time, causes are delayed, and multiple factors interact, single snapshots cannot capture the full picture.
The IACC Digital Twin™ model focuses on patterns over time, context, and lived experience. It is designed to function with incomplete information, limited energy, and real-world conditions. By separating observation from conclusions and preserving context, it supports clearer understanding and safer interpretation. In practice, this means patients can describe their experience without perfect records, clinicians can observe trends rather than isolated events, and researchers can study complex illness with greater accuracy. Although developed for infection-associated chronic conditions, the same principles apply wherever conditions change and cause and effect are not immediate. The goal is not to simplify reality, but to make complex patterns easier to see.
What is AIM™
Adaptive Intelligence Modeling (AIM™) is CYNAERA’s core logic framework for interpreting complex, fluctuating health data over time. It is designed for conditions where symptoms do not behave in straight lines and where timing, context, and system interactions matter more than single data points. Traditional models treat illness like a snapshot.AIM treats illness like a dynamic system. Instead of asking, “What is happening right now?”AIM asks, “What patterns are emerging across time, context, and system stress?”
Why AIM Exists
Many infection-related chronic illnesses do not follow predictable or linear paths. Symptoms may be delayed, triggers may overlap, and standard tests may appear normal despite significant dysfunction. AIM was built to interpret these nonlinear patterns safely and realistically.
Glossary
Activity Tolerance
How much physical or mental activity a person can do without symptoms getting worse.
Autonomic Nervous System
The body system that controls automatic functions like heart rate, blood pressure, breathing, and temperature.
Autonomic Dysfunction
When automatic body functions do not work properly, causing symptoms like dizziness, rapid heart rate, or fainting.
Brain Fog
Trouble with memory, focus, or clear thinking.
Context
Conditions around a person that may affect symptoms, such as weather, stress, sleep, or environment.
Delayed Response
When symptoms appear hours or days after a trigger instead of right away.
Environmental Exposure
Contact with factors like air pollution, mold, chemicals, or temperature changes that can affect symptoms.
Flare
A period when symptoms suddenly get worse.
Hormonal Changes
Natural shifts in hormones during menstrual cycles, menopause, stress, or illness that can affect symptoms.
Infection-Associated Chronic Conditions (IACCs)
Long-term illnesses that begin after an infection, such as Long COVID or ME/CFS.
Lived Experience
A person’s real-world experience of symptoms and daily life with illness.
Mast Cells
Immune cells involved in allergic reactions and inflammation.
Mast Cell Activation
When mast cells release chemicals that cause symptoms like flushing, rapid heart rate, or sensitivity to foods and smells.
Observation
What a person notices happening in their body or environment, without drawing conclusions.
Pattern
Changes that repeat over time, such as symptoms worsening after activity or during certain weather.
Post-Exertional Worsening
Symptoms getting worse hours or days after physical or mental activity.
Stability
A period when symptoms remain within a person’s usual range.
Trigger
An event or exposure that may lead to symptom changes.
Over Time
Looking at changes across days, weeks, or months instead of a single moment.
Foundational theory and system behavior
Minimum Viable Data, pattern mapping, and phenotype logic
Remission sequencing and trial interpretation
Environmental volatility and flare risk
Prevalence correction and surveillance framing
Mechanism-based substitution and repurposing logic
GPTs Referenced
This document serves as a shared reference for patients, clinicians, researchers, and CYNAERA AI systems. The frameworks described are observational and educational. They do not provide medical care or individualized treatment guidance. Instead, they support clear communication and pattern-based interpretation in conditions characterized by variability and delayed response.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Afrin, L. B., Pohlau, D., & Raithel, M. (2016). Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain, Behavior, and Immunity, 50, 314–321.
Angum, F., Khan, T., Kaler, J., Siddiqui, L., & Hussain, A. (2020). The prevalence of autoimmune disorders in women: A narrative review. Cureus, 12(5), e8094.
Crook, H., Raza, S., Nowell, J., Young, M., & Edison, P. (2021). Long COVID—mechanisms, risk factors, and management. BMJ, 374, n1648.
Davis, H. E., Assaf, G. S., McCorkell, L., et al. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 38, 101019.
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21, 133–146.
Greenhalgh, T., Knight, M., A’Court, C., Buxton, M., & Husain, L. (2020). Management of post-acute COVID-19 in primary care. BMJ, 370, m3026.
Institute of Medicine. (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press.
Iwasaki, A., Putrino, D., & colleagues. (2023). Immune and inflammatory drivers of Long COVID. Nature, 620, 574–585. (Note: aligns with immune dysregulation references used in document context.)
Jason, L. A., Sunnquist, M., & Brown, A. (2018). Post-exertional malaise in ME/CFS: A review of the evidence. Journal of Translational Medicine, 16, 343.
Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. Nature Reviews Immunology, 16, 626–638.
Klimas, N. G., Broderick, G., & Fletcher, M. A. (2012). Biomarkers for chronic fatigue. Brain, Behavior, and Immunity, 26(8), 1202–1210.
Komaroff, A. L., & Bateman, L. (2021). Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Frontiers in Medicine, 7, 606824.
Meadows, D. H. (2008). Thinking in Systems: A Primer. Chelsea Green Publishing. (Supports systems framing in UNCT and cross-sector applicability.)
Miglis, M. G., Prieto, T., Shaik, R., Muppidi, S., Sinn, D. I., & Jaradeh, S. (2020). A case series of postural tachycardia syndrome after COVID-19. Clinical Autonomic Research, 30, 449–451.
National Academies of Sciences, Engineering, and Medicine. (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press.
Naviaux, R. K. (2016). Metabolic features of chronic fatigue syndrome. Proceedings of the National Academy of Sciences, 113(37), E5472–E5480.
Raj, S. R., Arnold, A. C., Barboi, A., et al. (2022). Long-COVID postural tachycardia syndrome: An American Autonomic Society statement. Clinical Autonomic Research, 32, 365–368.
Raj, S. R. (2013). Postural tachycardia syndrome (POTS). Circulation, 127(23), 2336–2342.
Theoharides, T. C., Tsilioni, I., & Ren, H. (2020). Recent advances in our understanding of mast cell activation—or should it be mast cell mediator disorders? Expert Review of Clinical Immunology, 16(6), 639–656.
Comments